Lymphoma, B-Cell: all 1,415 studies
Page 11 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03344367Phase 1
- B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCompletedNCT03332121Phase 1
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma PatientsStatus unknownNCT03318835Phase 3
- A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedNCT03314922Phase 1
- Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceCompletedNCT03311958Early Phase 1
- A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell LymphomaCompletedNCT03307746Phase 1/2
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownNCT03299738Phase 1
- A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
- Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk FactorsCompletedNCT03283202Phase 1
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
- Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell LymphomaStatus unknownNCT03281551Phase 1
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLCompletedNCT03259529Phase 1/2
- Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell LymphomaStatus unknownNCT03258047Phase 2
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
- Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHLStatus unknownNCT03245905Phase 2
- Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyActive, not recruitingNCT03244176Early Phase 1
- BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCTStatus unknownNCT03229616Phase 2/3
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruitingNCT03229200Phase 4
- A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell LymphomasCompletedNCT03218072Phase 1
- Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
- Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)CompletedNCT03211702
- Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT03208556Phase 1
- Chidamide With R-CHOP Regimen for DLBCL PatientsStatus unknownNCT03201471Phase 2
- Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell LymphomaCompletedNCT03200015Phase 2
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasCompletedNCT03161054Phase 2
- Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
- R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCLStatus unknownNCT03151044Phase 3
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
- CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.Status unknownNCT03146533Phase 1/2
- Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
- Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
- 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell LymphomaActive, not recruitingNCT03121456Not applicable
- A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenanceActive, not recruitingNCT03114865Phase 1/2
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
- Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Status unknownNCT03105596Phase 2
- Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03104478
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
- The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaStatus unknownNCT03101709Phase 1
- Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
- Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
- Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT03072771Phase 1
- Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT03064867Phase 1/2
- A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownNCT03060850Phase 1
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasCompletedNCT03036904Phase 1
- CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaCompletedNCT03029338Phase 1
- The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell LymphomaStatus unknownNCT03022123Not applicable
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
- Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialCompletedNCT03003546Phase 1
- A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaCompletedNCT03003039Phase 1
- The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
- HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeStatus unknownNCT03000192
- Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell LymphomaStatus unknownNCT02992834Phase 4
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCTCompletedNCT02992223
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedNCT02976857Phase 1
- Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ LymphomaStatus unknownNCT02965157Phase 1/2
- A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
- A Phase II Study of the FIL on Elderly Frail Patients With DLBCLCompletedNCT02955823Phase 2
- RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
- Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Phase 1
- Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 1
- Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin LymphomaCompletedNCT02920697Phase 1
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
- Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
- Erythropoietin for Management of Anemia Caused by ChemotherapyCompletedNCT02890602Phase 2
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
- Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric OncologyCompletedNCT02847130
- p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid MalignanciesCompletedNCT02846935Early Phase 1
- Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT02842138Phase 1
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedNCT02836925Phase 2
- Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic MalignanciesStatus unknownNCT02813837Not applicable
- Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic ToolStatus unknownNCT02791217
- Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT02787239Phase 3
- AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
- CNS Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT02777736Phase 3
- T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell MalignanciesStatus unknownNCT02772198Phase 1/2
- Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT02767674Phase 3
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
- Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT02752204Phase 2
- Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCLStatus unknownNCT02747732Phase 2
- A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDPCompletedNCT02741388Phase 1
- the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Status unknownNCT02737085Phase 1/2